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Neuropeptides drive a wide diversity of biological actions and mediate multiple regulatory functions involving all organ systems.
They modulate intercellular signalling in the central and peripheral nervous systems as well as the cross talk among nervous
and endocrine systems. Indeed, neuropeptides can function as peptide hormones regulating physiological homeostasis (e.g.,
cognition, blood pressure, feeding behaviour, water balance, glucose metabolism, pain, and response to stress), neuroprotection,
and immunomodulation. We aim here to describe the recent advances on the role exerted by neuropeptides in the control of
autophagy and its molecular mechanisms since increasing evidence indicates that dysregulation of autophagic process is related to
different pathological conditions, including neurodegeneration, metabolic disorders, and cancer.
1. Neuropeptides
Secretory peptides are short chains of amino acids linked
together via peptide bonds which function primarily as
signalling molecules in animals. In the 1970s an endogenous
peptide was found in nerve cells and the term neuropeptides
was then introduced [1]. Aftermany years of intense research,
there is a general agreement that neuropeptides are widely
distributed throughout the central and peripheral nervous
systems; they commonly act as complementary signals to
“classic” neurotransmitters to fine-tune the neurotransmis-
sion, thereby controlling the balance between excitation
and inhibition [2–4]. Neuropeptides may be costored or,
alternatively, may coexist with other messenger molecules,
as, for instance, with one or even two small classical neuro-
transmitters, in different cellular compartments. It is a general
rule that when a peptide and a classical transmitter coexist,
the former mediates long-lasting responses and the latter
short-term synaptic events in the target cells. Since neuropep-
tides are mainly present in neurons and glial cells but are
also widely expressed in nonneural cells and tissues/organs,
that is, endocrine and immune systems, their functions
range from neuromodulators, neurohormones/hormones,
and immune-modulators to growth factors [2–7]. In this
scenario, neuropeptides may act in the cross talk among ner-
vous, endocrine, and immune systems through neurocrine,
paracrine, autocrine, and endocrine manners thus influenc-
ing the postsynaptic cells and large target areas; of interest the
same peptides may participate in cellular communications
through differentmodalities. Chemically, neuropeptides have
a less complex three-dimensional structure and are smaller
(3–100 amino acid residues long) than normal proteins
but are larger than classic neurotransmitters. More than
100 different neuropeptides are currently described in cell
signalling (http://www.neuropeptides.nl).
Almost all peptidergic receptors belong to the superfam-
ily of heterotrimeric G-protein coupled receptors (GPCRs)
which are characterised by the presence of 7 transmem-
brane domains; but there are some exceptions, such as the
ionotropic receptor for the FMRFamide and two neurotensin
receptors [3–5]. Of interest, recent evidence challenges the
central tenet that GPCR activity induced by neuropeptides
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originates exclusively at cell membrane level [8]. Commonly
there are several receptor subtypes for a given peptide ligand
and many naturally occurring peptides exhibit a high degree
of promiscuity across GPCRs [4, 5].
2. Autophagy, a Brief View
Autophagy is an evolutionarily conserved membrane process
involved in the replacement of cell components in both
constitutive and catabolic conditions through which it plays
important roles in cell functions including development,
inflammation, metabolism, and aging. Autophagic process
acts in a physiological manner to degrade cytoplasmic con-
stituents, proteins, protein aggregates, and whole organelles,
which are engulfed in autophagosomes which then fuse with
lysosomes to form autolysosome for degradation [9, 10].
However, the role of autophagy extends beyond the general
removal/recycling of damaged elements to many specific
homeostatic and pathological processes [11–14].
The most prevalent form of autophagy is macroau-
tophagy, usually simply referred to as autophagy, which is
characterised by membranes that gradually grow in size
to generate double membrane-structures (i.e., autophago-
somes).This involves three main steps: initiation, nucleation,
and expansion [9, 10, 15]. Autophagosomes recognize and
sequester cellular cargo, that is, organelles, small portion
of cytosol, or protein aggregates, that has been tagged by
autophagy adaptors [9, 13, 15]. Cargo is then degraded by
lysosomal hydrolases. Cellular cargo recognitionmay depend
on ubiquitination, although nonubiquitinated cargo is also
cleared by autophagy [16]. The molecular signalling pathway
leading to autophagy is very complex and regulated by
autophagy-related genes (Atgs), many of them were first
identified fromyeast, which are connectedwith the formation
of autophagosomes. Atg-complexes are also controlled by
several signalling pathways that fine-tune autophagy to reg-
ulate the pace of autophagosome formation. Different recent
reviews have extensively reported the detailed description of
the autophagic process and its regulation [9, 13, 15].
For an adequate interpretation of the data autophagy
would be measured by multiple assays and monitored
dynamically over time in order to assess if autophagic sub-
strates have reached the lysosome/vacuole andwhether or not
they have been degraded [10, 17]. For instance, the clustering
of microtubule-associated protein 1 light chain 3 (LC3) pro-
tein, a homolog of the yeast protein Atg8, and its association
with autophagosomes membranes have been established as
useful sign to monitor autophagy, since LC3 present in
the autophagosome membrane recognizes autophagic recep-
tors/adaptors of cargos [10, 17]. During autophagy, the cyto-
plasmic form of LC3-I (18 kDa) is recruited to phagophores
where LC3-II (16 kDa) is generated by proteolysis and lipida-
tion at the C-terminus.Thus LC3-II formation positively cor-
relates with the number of autophagosomes [10, 17]. However,
the lipidation and clustering of LC3 may be the result of both
induction and suppression of autolysosomal maturation. In
this respect, a key point in autophagy studies is that there
is a difference between monitoring the autophagic elements
(number or volume of autophagosomes/autolysosomes) and
measuring autophagic flux during the autophagic process, as,
for instance, the amount and rate of cargo sequestered and
degraded [10, 17].
At the beginning autophagywas considered as a nonselec-
tive degradation mechanism, but now it is clear that selective
forms of autophagy occur [10]. Depending on cell type,
induction or suppression of autophagy may exert protective
effects [18, 19] and altered autophagy is related to several
pathologies including cancer, nervous system diseases, neu-
rodegenerative diseases, infectious diseases, and metabolic
or endocrine diseases [11–14, 20–30]. Of notice, autophagy is
essential for the survival of neural cells since basal autophagy
may prevent the accumulation of abnormal proteins which
can disrupt neural function leading to neurodegeneration
[31–33]. Autophagy is also important to accommodate the
complicated architecture of neurons and their nondividing
state [28]; within the endocrine system autophagy plays
a critical role in controlling intracellular hormone levels,
targeting both the secretory granules and the hormone-
producing organelles [14].
3. Neuropeptidergic Systems in Autophagy
We have highlighted here recent findings that provide infor-
mation on neuropeptide actions in regulating autophagy
(Table 1), with an emphasis on their signalling features
and pathophysiological role. Since neuropeptides are mainly
present in the central nervous system but are also widely
expressed and active in nonneural cells and peripheral
tissues/organs, their actions have been reported in a broad
spectrum of targets. This may also represent a confounding
factor since neuropeptides often lack specificity at cellular
levels as their signals have multiple functions.
3.1. Pituitary Adenylate Cyclase-Activating Polypeptide. Hy-
pothalamic neurons are known to synthesise several neu-
ropeptides with a variety of central and peripheral functions
[34]. Among them, pituitary adenylate cyclase-activating
polypeptide (PACAP) is amember of the vasoactive intestinal
peptide/secretin/glucagon family of peptides. In the nervous
system PACAP acts as a multifunctional peptide regulating
neurotransmission, hormonal secretion, neuronal survival,
neuroprotection, and neuroimmune responses [6, 35]. The
peptide is also a potent antiapoptotic, anti-inflammatory, and
vasodilating substance.
It has been observed that PACAP has protective effects
in animal models of Parkinson disease (PD) [36], a chronic
and progressive disorder which is characterised primarily
by the selective loss of dopaminergic neurons in the sub-
stantia nigra pars compacta leading to a dopamine deficit
in the striatum. Increasing evidence suggests that dysregu-
lation of autophagy results in the accumulation of abnor-
mal proteins and/or damaged organelles which is com-
monly observed in neurodegenerative diseases, including PD,
although whether such dysregulation of autophagy is the
cause or the consequence of PD pathology remains unclear
[29, 37, 38]. LC3-II levels were found to be elevated in the
substantia nigra pars compacta and amygdala of PD brain
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samples; in addition lysosomal proteins were reduced thus
suggesting a link between a defect in autophagy and PD
[39]. Numerous studies in both in vitro and in vivo animal
models reported that the application of autophagy activa-
tors decreases dopaminergic neurodegeneration, supporting
the potential therapeutic effects of autophagy modulators
in PD, although other researches also report the possible
harmful role of autophagy [29, 37]. Of interest, inactivation
of autophagy by deleting the autophagy gene Atg7 predis-
poses animals to PD-like pathology [40]. Conversely, it has
been recently demonstrated that the upregulation of Atg7
increases autophagy and is deleterious for dopaminergic
neurons survival [41]. Products of Atg7 are essential for the
activation (lipidation) of the LC3 [9, 10, 15]. In in vitro and in
vivo experimental models of PD and PACAP displayed not
only antiapoptotic but also antiautophagic properties since
they decreased autophagic vacuole formation and lipidated
LC3 levels and the expression of the autophagosomal cargo
protein p62 [42], which serves as a link between LC3 and
ubiquitinated substrates. PACAP also supported the correct
mitochondrial function in neurons which are committed
to die [42], thus suggesting its protective role during the
aberrant mitophagy induced by PD.
3.2. Substance P. Substance P (SP) belongs to tachykinins
family, which includes neuropeptides expressed in neuronal
and in nonneuronal cells, as well as in noninnervated tissues
[6, 43]. Among its multiple roles, SP was recently associated
with increased autophagy in mouse models of chronic psy-
chological stress condition [44]. In particular, SP increased
skin levels of LC3-II and beclin-1, themammalian orthologue
of yeast Atg6 involved in autophagosome formation and
maturation [9, 10, 15]. Of notice, SPwas also shown to activate
hyperactive bladder afferent signalling by LC3-II-mediated
autophagy [45]. However, these results remain controversial
since the autophagosome turnover was not investigated.
3.3. Agouti-Related Peptide and Proopiomelanocortin Peptides.
Individual hypothalamic neuronal populations can control
the body homeostasis, neuroendocrine outputs, and feeding
behaviour [46]. In particular, neurons of the arcuate nucleus
of the hypothalamus release specific neuropeptides that
regulate feeding. Some of them increase food intake, such
as orexigenic agouti-related peptide (AgRP); some others
act in feeding suppression, as the anorexigenic proopiome-
lanocortin (POMC) synthesised by POMC neurons.
Several lines of evidence suggest a role of autophagy in
the neuropeptidergic regulation of food intake and energy
balance and that the regulation of hypothalamic autophagy
could become an effective intervention in conditions such as
obesity and themetabolic syndrome.The loss ofAtg7 inAgRP
neurons reduced AgRP levels, food intake (in particular
refeeding response to fasting), and adiposity [47]. In contrast,
deletion of Atg7 in POMCneurons increased food intake and
bodyweight [48]. Similar results were obtained in the absence
of Atg12 but not Atg5 [49]. In addition, selective loss of
autophagy (i.e., loss of Atg7) in POMC neurons decreased 𝛼-
melanocyte-stimulating hormone levels (an active derivative
of POMC), increased body weight, and raised adiposity and
glucose intolerance likely controlling energy balance [50,
51]. These metabolic impairments were associated with an
accumulation of p62-positive aggregates in the hypothalamus
and a disruption in the maturation of POMC-containing
axonal projections [51]. It has been recently shown that, in
hypothalamic cell lines subjected to low glucose availability,
autophagy was induced via the activation of the protein
kinase AMPK, which regulates the mammalian target of
rapamycin (mTOR) pathway, one of the most important
upstream inhibitors of the autophagic process [9], followed by
decreased POMC expression [52]. Of interest the knockdown
of the AMPK in the arcuate nucleus of mouse hypothalamus
fed with high-fat diet decreased autophagic activity and
increased POMC expression, leading to a reduction of food
intake and body weight [52]. Accordingly, the impairment of
POMC-derived production of adrenocorticotropin hormone
was correlated with the induction of endoplasmic reticulum
stress and autophagy in the pituitary glands of sucrose-
rich diet-treated rats; noteworthy these effects are reversed
by moderate exercise which has a beneficial role in insulin
resistance [53]. Together, these data provide evidence that
autophagy in POMC/AgRP neurons is required for normal
metabolic regulation, neural development, and control of
feeding.
3.4. Neuropeptide Y. Nutrient deprivation (or caloric restric-
tion) can stimulate autophagy and the orexigenic peptide
neuropeptide Y (NPY) in hypothalamic and cortical neurons
[54]. NPY is one of the most abundant neuropeptides within
the brain and exerts (through its receptors, named Y1 to 6) an
important role in many physiological functions such as food
intake, energy homeostasis, circadian rhythm, cognition,
stress response, neurogenesis, and neuroprotection [6, 55–
58].
In mouse hypothalamic neuronal cell line and in rat
differentiated hypothalamic neural cells, NPY increased neu-
ronal autophagic flux as shown by the analysis of LC3-
II turnover, the decrease of p62, and the increase in the
number of autophagosomes and autolysosomes [54]. This
effect is exerted by the activation of Y1 or Y5 receptors.
The signalling pathway associated with the induction of
autophagy byNPY involved the activation of different protein
kinases, including PI3K, ERK1/2-MAPK, and PKA. The
NPY-induced autophagic flux stimulation was confirmed in
mice hypothalamus by in vivo overexpression of NPY in
arcuate nucleus [54]. Moreover, in rat cortical neurons NPY
stimulates autophagy (i.e., the increase of LC3-II and the
decrease of p62 expression) likely through the inhibition
of mTOR activity [59]. In mice fed with high-fat diet, the
deletion of AMPK activity in the arcuate nucleus of the
hypothalamus decreased autophagy andNPYexpression thus
reducing food intake and body weight [52]. Accordingly,
in hypothalamic cell lines, autophagy was induced via the
activation of the protein kinase AMPK, modulating mTOR
signalling and increasing NPY levels [52].
Since both autophagy and NPY level decrease with age,
strategies to promote autophagy and increase NPY, including
the caloric restriction, were suggested to produce protective
effects delaying the impairments associated with longevity
BioMed Research International 5
[54, 59, 60]. Modulating hypothalamic autophagy might
have also implications for preventing obesity and metabolic
syndrome of aging [47, 50]. Finally, NPY exerted a neuropro-
tective effect in the striatum and cerebellum of two mouse
models of the spinocerebellar ataxia type 3 [61], a disease
characterised by autophagic defects. Authors thus suggested
that this action may be related to an activation of protein
clearance mechanisms such as autophagy, even though addi-
tional data are mandatory to support this hypothesis [58,
61]. Overall, the potential of NPY to delay neurodegener-
ation through autophagy stimulation as a strategy to clear
abnormal, misfolded proteins that cause neurodegenerative
diseases deserves to be investigated in detail.
3.5. Ghrelin and Leptin. Ghrelin is a peptide produced
primarily in the stomach and secreted into the systemic
circulation. It exhibits various biological actions such as
regulation of food intake, gastrointestinal motility, and
energy homeostasis [62]. The adipokine leptin, the “satiety
hormone,” is a peptide made by adipose cells that helps to
regulate energy balance [63]. Ghrelin, the “hunger hormone,”
and leptin actions are opposed. Both hormones function as
neuropeptides in the hypothalamus regulating feeding.
Recent evidence suggests that ghrelin reduced mouse
liver fibrosis and this event correlates with the decrease
of LC3-II and an increase of p62 expression in fibrotic
liver tissues [64]. Also, ghrelin promoted the cardiomyocyte
survival and size maintenance during cardiac dysfunction
by suppressing the excessive autophagy, as demonstrated
by the decrease of LC3-II levels and autophagic vacuoles.
This effect parallels the upregulation of mTOR pathway
which likely acts in an AMPK-suppressed and p38-MAPK-
activated manner [65]. In contrast, ghrelin stimulated insulin
levels in skeletal muscles of diabetic mice, thus restoring the
suppressed mTOR-dependent autophagy [66]. Accordingly,
in human ovarian epithelial carcinoma cells, ghrelin inhibited
mTOR, enhanced LC3-II levels, and, consequently, induced
apoptosis [67]. Similarly, under caloric restriction ghrelin and
NPY synergise in rat cortical neurons, stimulating autophagic
flux by inhibition of mTOR [59]. Since autophagy disruption
occurs in aging and age-related neurodegenerative diseases,
the effects of NPY and ghrelin on autophagy activation
indicate a therapeutic potential to delay aging process. In
response to calorie restriction, growth hormone (GH) and
liver LC3-II increased in order to maintain blood glucose
level; ghrelin promotes GH secretion suggesting a mecha-
nism for the antihypoglycaemic role of the peptide in fasted,
fat-depleted mice [68].
A crucial role of autophagy was recently reported in
leptin-induced proliferation of hepatic and breast cancer cells
using both in vitro and xenograft models [69]. In partic-
ular, leptin caused activation of autophagy and autophago-
some formation via upregulation of p53/FoxO3 axis thus
favouring tumour growth and, likely, tumour invasion. In
addition, the liver condition of leptin-deficient obese mice
has been associated with a blockade of autophagy although
data are controversial and a measurement of autophagic
flux/autophagosome formation is lacking [70]. Of interest,
the fact that leptin induces autophagy and acts in the patho-
genesis of obesity raises the possibility of a role connecting
obesity and the development of cancer caused by leptin
production.
3.6. Somatostatin, Orexin A, and Gastrin-Releasing Peptide.
Other neuropeptides are suggested to be involved in can-
cer initiation and progression through the modulation of
autophagy. Somatostatin or somatotropin release inhibiting
factor (SRIF) is a small peptide that is classically considered
the key endogenous inhibitor of GH from the hypothalamus
[71–76]. SRIF is present in many regions of the central
and peripheral nervous systems but also in peripheral non-
neuronal tissues, such as gastrointestinal tract, endocrine
organs, and cells of the immune system [76–80]. Func-
tionally, SRIF acts as neurotransmitter/neuromodulator and
carries out inhibitory actions on the secretion of many
biologically active substances [76, 79, 81–85]. Somatostatin
analogues are the current mainstay treatment for acromegaly
and gastroenteropancreatic neuroendocrine tumours [86].
It has been recently suggested that preoperative treatment
with SRIF agonists of patients with acromegaly increased
autophagy and decreased cell proliferation in ex vivo samples
ofGH-secreting adenomas [87]. In particular, SRIF treatment
determined a significant decrease of immunopositivity of
beclin-1 and an increase of Atg-5 staining, which is a factor
inducing LC3-II and autophagosome formation [9, 10, 15].
Orexins (or hypocretins) are hypothalamic neuropep-
tides that regulate arousal, wakefulness, and appetite [88].
Orexin A has been shown to induce the formation of
autophagic vacuoles, the lipidation of LC3-II, and the increase
of beclin-1 expression in human colon cancer cells [89]. The
orexin A-induced effects occurred through the upregulation
of ERK pathway. In addition, the gut neuropeptide called
gastrin-releasing peptide and its receptor are expressed in
neuroblastoma cells and promoted angiogenesis, tumorigen-
esis, and metastatic potential. Noteworthy, enhanced mTOR-
dependent autophagy blocked angiogenesis via degradation
of gastrin-releasing peptide [90].
3.7. Angiotensin II. The angiogenic process and vascular
endothelial status involve the role of angiotensin II (Ang-
II), a peripheral hormone that increases blood pressure
through vasoconstriction. Ang-II also acts as a neuropeptide
in the central nervous system and is involved in neuronal
dysfunction [91].
Different studies suggested that autophagy has a pro-
tective effect on vascular damage due to Ang-II since it
is able to remove damaged mitochondria and other cel-
lular organelles. For instance, in human umbilical vascu-
lar endothelial cells, Ang-II induced cell senescence and
apoptosis and increased the number of autophagosomes,
LC3-II, and beclin-1 expression [92]. Also, Ang-II increased
autophagic flux in vascular smooth muscle cells through the
production of mitochondrial reactive oxygen species [93].
In the kidney, Ang-II increased autophagosome number of
podocyte and the expression of autophagic genes such as
LC3-II and beclin-1, via the generation of reactive oxygen
species [94, 95]. Autophagy may thus have a role also in
preventing the progression of proteinuria. In cultured neona-
tal rat ventricular cardiomyocytes it has been reported that
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Ang-II-stimulated cardiomyocyte hypertrophy upregulated
the expression of LC3-II as well as the number of autophagic
vacuoles and the inhibition of Ang-II-induced effects on
autophagy has been suggested to protect against pathological
myocardial hypertrophy [96]. In this respect, it should be
noted that a dual role of Ang-II has been reported in heart
failure associated with autophagy modulation since some
authors suggested that autophagy activation attenuated Ang-
II-induced hypertrophy and vice versa [97].
3.8. Intermedin, Urocortin 1, and Brain Natriuretic Peptide.
Intermedin (or adrenomedullin 2) is a POMC-derived neu-
ropeptide produced by hypothalamus, pituitary, and several
peripheral tissue cells with many physiological functions
[98]. A role of intermedin in attenuation of myocardial
infarction implicates the increase of LC3-II in a rat model
of ischemic heart failure although the autophagic dynamics
remains unclear [99]. Similarly, intermedin increased lip-
idated LC3 and autophagosome numbers in hypertrophic
hearts of mice and cultured cells through the activation of
both cAMP/PKA and ERK1/2-MAPK pathways, leading to
the decrease in cardiomyocyte size and apoptosis [100].
Urocortin 1, a 40-amino acid peptide belonging to the
corticotropin-releasing factor family, is another neuropeptide
released in many areas of the brain but also in periphery
including cardiac tissue [101, 102]. In particular, urocortin 1 is
upregulated in the unhealthy heart and has a cardioprotective
role [102, 103]. Of notice, it decreased autophagy and cell
death in cardiomyocytes exposed to ischemia/reperfusion
injury by reducing beclin-1 expression [104]. This effect
involved the activation of PI3K/Akt signalling pathway and
did not require ERK1/2-MAPK.
Brain natriuretic peptide (or ventricular natriuretic pep-
tide) is a 32-amino acid polypeptide mainly secreted by the
ventricles of the heart in response to excessive stretching of
cardiomyocytes but also is present in the central nervous
system where it represents an important neuromodulatory
system [105]. A case report study in a 75-year-old man
without overt heart failure showed augmented plasma levels
of brain natriuretic peptide which may be responsible for the
presence of conspicuous autophagic vacuoles in cardiomy-
ocytes [106].
4. Conclusion
The current consensus is that autophagy’s role as regards cell
death is primarily protective [18, 19]. Indeed, in most cells,
autophagy occurs at basal levels but is often increased under
adverse conditions to confer stress resistance and promote
cell survival, as an important cytoprotective mechanism.
On the other hand high or excessive levels of autophagy
may induce “autophagy cell death” [18, 19], a term used to
describe cell death that is suppressed by downregulating the
autophagy machine [19]. As reviewed here, recent observa-
tions, although preliminary, indicate a role for endogenous
neuropeptides in the regulation of autophagy which deserves
to be further investigated. This may provide a better knowl-
edge of the molecular mechanisms and functional dynamics
of autophagic process as well as its pathophysiology.
The clinical potential of neuropeptides is well known
and, needless to say, the multiplicity of peptidergic receptors
and the features of peptidergic transmission offer unique
and important openings for the development of specific new
drugs [2–7]. The study of neuropeptides in the biology of
autophagy has the potential for facilitating the development
of autophagy-based therapeutic interventions [107], target-
ing, for instance, neurodegeneration, metabolic disorders,
cancer, and infection by different pathogens. For instance,
urocortins and other endogenous neuropeptides such as
vasoactive intestinal peptide, adrenomedullin, corticotropin-
releasing hormone, ghrelin, andmelanocyte-stimulating hor-
mone have been shown to exhibit antimicrobial proper-
ties against Trypanosoma brucei promoting an energetic
metabolism failure that triggers autophagic-like cell death
[108].
The activation of autophagymay be of therapeutic benefit
although there are also circumstances in which autophagic
induction permits pathogenesis [18, 19]. Due to its dual
pathophysiologic role, autophagy has been the subject of
intensive study, in order to gain a better knowledge of
its molecular mechanism and to discover new therapeutic
targets. In this respect, for the treatment of autophagy-
relevant human diseases, both pharmacologic activators and
inhibitors of autophagic process are of interest as potential
new drug candidates [30, 109, 110]. In this context, the
neuropeptide system might be an exciting challenge.
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